

SPECTRUM PHARMACEUTICALS INC

Form 8-K

March 11, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported): March 7, 2008  
SPECTRUM PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other Jurisdiction  
of Incorporation)**

**000-28782  
(Commission File Number)**

**93-0979187  
(IRS Employer  
Identification Number)**

**157 Technology Drive  
Irvine, California  
(Address of principal executive offices)**

**92618  
(Zip Code)**

**(949) 788-6700**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

On March 7, 2008, we issued a press release announcing that we received marketing approval from the U.S. Food and Drug Administration, or FDA, for levoleucovorin for injection. It is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. Levoleucovorin is the only commercially available formulation comprised only of the pharmacologically active enantiomer of leucovorin (Levoleucovorin or (6S)-leucovorin). We currently expect commercial launch by June 2008.

In April 2006, we acquired the oncology drug product assets of Targent, Inc., which included a license agreement with Merck Eprova AG, a Swiss corporation, or Eprova, for levoleucovorin. Pursuant to the terms of the acquisition, we are required to issue to Targent, or its stockholders, an aggregate amount of 125,000 shares of our common stock, with a fair market value of \$305,000, upon the receipt of FDA approval. One-third of the shares were registered for resale pursuant to a registration statement that we filed on June 15, 2006, and is now effective.

Pursuant to the license agreement with Eprova, we are required to pay Eprova \$100,000.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibits:</b>	<b>Description of Document</b>
99.1	Press Release dated March 7, 2008.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 11, 2008

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Shyam Kumaria  
Name: Shyam Kumaria  
Title: V.P. Finance

3

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibits:</b>	<b>Description of Document</b>
99.1	Press Release dated March 7, 2008.
	4